InvestorsHub Logo
Followers 523
Posts 6631
Boards Moderated 1
Alias Born 07/24/2012

Re: None

Thursday, 10/25/2012 8:58:10 PM

Thursday, October 25, 2012 8:58:10 PM

Post# of 130513
While these developments are of significant importance for the Company, advancing MANF as a disease-modifying treatment for Parkinson's disease continues to be our primary focus. We anticipate announcing interim results from on-going delivery experiments by the end of October.